Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New therapy aims to help psychosis patients quit cannabis

NCT ID NCT07245212

Disease control Sponsor: King's College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a talking therapy called the Cannabis Clinic for Psychosis (CCP) to help people with first-episode psychosis reduce or stop cannabis use. The therapy includes motivational interviewing and cognitive behavioral therapy in weekly sessions over 12 weeks. Researchers will compare the therapy group to a waiting-list group receiving usual care, measuring changes in cannabis use. The goal is to see if this approach can improve outcomes and reduce relapses.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
psychosocial intervention (motivational interviewing and cognitive behavioral therapy)
What this could lead to
If it works, this could provide an effective non-drug treatment to help people with psychosis cut down or quit cannabis, potentially reducing relapses and hospital stays.
What could go wrong
This is a small early-stage trial with only 80 participants, and it uses a waiting-list design. The therapy may not work for everyone, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * First episode psychosis Community Mental Health teams receiving care under of SLaM Early Intervention for Psychosis Adult Mental Health Teams * CUDIT≥9 (Dependent on Cannabis) * age=18 to 65 years old ( age range of adult psychiatric services) * Capacity to give informed consent, as assessed by clinical teams Exclusion Criteria: * Lack capacity to consent * High levels of suicidal ideation, judged by clinical team -≥2 days/week frequency use of any other illicit drug * Participation in any other current intervention trial * In active crises and/or expressing suicidal ideations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence psychotic disorder Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use disorder First episode psychosis (FEP) Psychosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Marina House

    London, SE5 8RZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.